Boehringer Ingelheim Closes Deal With Pfizer

Published: 26-Oct-2009

To acquire a portion of the Fort Dodge Animal Health business

Boehringer Ingelheim has closed its deal with Pfizer to acquire a portion of the Fort Dodge Animal Health business.

The acquisition, which includes products in the US, Australia, Canada and South Africa, as well as two manufacturing and research facilities located in Fort Dodge, Iowa, will increase the size of Boehringer Ingelheim's companion animal and cattle portfolios.

Reportedly, the terms of the deal were not disclosed. Products being acquired in Europe are still subject to approval by European anti-trust authorities.

The company said that as part of the deal, Boehringer Ingelheim is expected to acquire the Duramune line of vaccines for dogs, the Fel-O-Vax line of vaccines for cats, and the Rabvac line of rabies vaccines manufactured and sold in the US, Canada and Australia.

In addition, a portfolio of pet and equine pharmaceutical products currently sold in the US is also included in the deal. The company will also acquire cattle vaccines in the US and Canada including the Triangle, Pyramid, and Presponse vaccine lines.

The pharmaceutical products being acquired include Cydectin (moxidectin) for cattle and sheep as well as Polyflex (ampicillin sodium). The dairy portfolio includes the key brands Today and Tomorrow. Several Canadian swine vaccines are included in the acquisition as are some cattle vaccines sold in Europe and South Africa.

Hubertus von Baumbach, member of the board of managing directors for Boehringer Ingelheim responsible for Finance and Animal Health, said: “With the closing of this deal, our attention now turns to ensuring a seamless integration of the highly committed teams of people as well as the transition of the product portfolio. We aim to jointly execute a robust business strategy that ensures the continued growth of our animal health business in the US and globally by continuously providing innovation to our customers."

Tell your friend about this article